Celsion takes a nosedive as board recommends trial halt; Three biotech IPOs set terms above $90M
→ Celsion’s stock has fallen down a drainpipe after the biotech disclosed this morning that their independent review board recommended they stop the Phase II trial on their lead drug, for primary liver cancer, after the board determined it was unlikely to reach its primary endpoint. Celsion said they would review the data before making a final decision. The stock $CLSN was down 65%, from $3.58 to $1.22.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
